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A B S T R A C T
The purpose of this study was to analyze the epidemiological situation of prostate cancer in Belgrade population.
Morbidity data were obtained from the Institute of Public Health of Serbia for the period 1999–2005. Mortality data for
the period 1990–2006, were derived from the Statistical Office of Republic of Serbia. Average standardized incidence and
mortality rates for the prostate cancer were 33.57 and 11.86 respectively. Standardized incidence rates of prostate cancer
steadily increased from 29.34 per 100,000 in 1999 to 36.86 per 100,000 in 2005. In the observed period, the mortality
rates significantly increased in the age groups 50–59 (y=2.77+0.42x, p=0.015), 70–79 (y=61.92+10.70x, p=0.000) and
80+ (y= 183.08+19.99x, p=0.000). The average annual percentage of changes (AAPC) was the highest (7.2%) for the
70–79 age group, the lowest (0.1%) for the youngest group(50), and 5% for the total. The increase of prostate cancer inci-
dence and mortality during the observed period in Belgrade population indicate urgent need for Serbian health profes-
sionals to adopt existing evidence-based cancer control and preventive measures. A national policy including prostate
specific antigen (PSA) screening should be considered.
Key words: incidence, mortality, trend, prostate cancer, Belgrade
Introduction
Prostate cancer is an important public health prob-
lem in the world although there are great differences be-
tween countries in both the level and trend of its morbid-
ity and mortality.
Prostate cancer represents the second most frequen-
tly diagnosed male cancer in the world with estimated
782,600 new cases in 2007. Nearly three-quarters of the
mentioned number are expected to be diagnosed in afflu-
ent countries. Internationally, the incidence of prostate
cancer varies for more than 50-fold1. The disease is re-
ported most frequently in the United States (standard-
ized incidence rate 124.8 per 100,000) where prostate
cancer is the most commonly diagnosed cancer in man2,3.
Incidence is also high in the western (61.6 per 100,000)
and northern Europe (57.4 per 100,000) and Austra-
lia/New Zealand (79.9 per 100,000). The lowest age stan-
dardized incidence rates are in North Africa (5.8 per
100,000) and in southern Central Asia (4.4 per 100,000)1.
Prostate cancer is the tenth leading cause of cancer
deaths in the world. It holds sixth place among men with
254,000 death cases in 20071. Looking at standardized
mortality prostate cancer rates in 2008, huge differences
persist among the countries of the world. The highest
rates (per 100,000) were recorded in Caribbean region
(26.3), South Africa (19.3) and Middle Africa (13.4), while
the lowest rates are in the Eastern (2.5) and Southern
Central Asia (2.8)4.
Trends in prostate cancer mortality rates have been
decreasing in many developed countries, such as USA,
Canada, UK, Sweden, Denmark, France and Australia,
while they are rising in Japan and Singapore2,5.
Continual monitoring of trends and patterns in both
high-risk and low-risk populations remains an important
element in etiologic research on prostate cancer as well
as in cancer control and prevention5.
The reasons for this high degree of variability among
countries are probably multi-factorial. They include in
the first place different availability of improved detection
methods although variability in diet and other risk fac-
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tors, including genetic and differences in treatment, could
also be of importance.
The aim of this descriptive study was to analyze the
epidemiological situation of prostate cancer among the
Belgrade population for the period 1990–2006.
Methods
In this study, the source of mortality data (1990–2006)
related to the male genital organ cancers (codes 185–187
according to the International Classification of Diseases,
ICD 9th revision and codes C60-C63, according to the ICD
10th revision), and all malignant tumors (codes 140–208,
ICD 9th revision and C00-C97, ICD 10th revision) was the
Belgrade Office of Statistics. Morbidity data were ob-
tained from the Institute of Public Health of Serbia for
the period 1999–2005. There are no relevant morbidity
data for the years that precede the mentioned period. As
denominator for rates, the average Belgrade male popu-
lation of two census years, 1991 and 2002 was used
(761,608).
Mortality and morbidity rates per 100,000 inhabit-
ants were standardized according to the Segi’s world
population6. To estimate the prostate cancer mortality
trend we performed regression analysis using SPSS ver-
sion 17.0 for Windows (SPSS Inc. Chicago, IL, USA). Lin-
ear trend was used whenever it significantly (p<0.05)
represented estimated mortality rates. The average per-
centage of annual changes (AAPC) with corresponding
95% confidence interval (95% CI) were calculated using
the Joinpoint regression program7 (Version 3.4.2 – Octo-
ber 2009). Tests of significance used a Monte Carlo per-
mutation method8.
Results
During the period 1999–2005 the average number of
prostate cancer incidence cases was 395 per year, which
was 86.6% of all male genital cancers, and 9.6% of all can-
cers in men. The average standardized incidence rate of
prostate cancer was 33.6 per 100,000 (Table 1).
During the period 1990–2006 the average number of
prostate cancer deaths was 135 per year, which accoun-
ted for 93.1% of all male genital cancers deaths and for
6.3% of all cancer deaths in men. The average standardi-
zed mortality rate of prostate cancer was 11.9 per 100,000
(Table 1).
The number of prostate cancer incidence cases has
been rising from one year to another, with the maximum
of 435 incidence cases reached in 2005. Standardized in-
cidence rate per 100,000 inhabitants was the lowest in
1999 (29.3), while the highest rate (36.9) was recorded in
2005 (Table 2).
During the 17-year period analyzed, 2,302 subjects
died from prostate cancer in Belgrade (Table 2). The to-
tal number of cancer deaths increased from 103 in 1990
to 204 in 2006. The lowest standardized mortality rate
was in 1993 (8.5) while the highest one was recorded ten
years later, in 2003 (18.6, Table 2).
Age-specific incidence rates incresed with age (Figure
1). The highest incidence rate was in the 70–79 age group
and the lowest among the people  50 years old. In all age
groups, the incidence rates showed a tendency of slight
increase, except in the oldest age group (80+) where de-
crease was recorded.
Prostate cancer mortality rates also increased with
age (Table 3). The lowest mortality rate was in the 50
age group and the highest among the people  80 years
old. In the observed period, the mortality rates signifi-
cantly increased in the age groups 50–59 (y=2.77+0.42x,
p=0.015), 70–79 (y=61.92+10.70x, p=0.000) and 80+
(y=183.08+19.99x, p=0.000). The AAPC was the high-
est (7.2%) for the 70–79 age group, the lowest (0.1%) for
the youngest (50), and 5% for all ages.
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TABLE 1
AVERAGE STANDARDIZED* INCIDENCE AND MORTALITY RATES (PER 100,000) OF PROSTATE CANCER, GENITAL ORGAN CANCERS
AND ALL CANCERS IN MALE POPULATION OF BELGRADE
Cancers (Codes according to the ICD 9th









Prostate (185, C61) 395 33.57 135 11.86
All genital organ cancers (185–187, C60-C63) 456 8.67 144 1.13
All cancers 4115 341.70 2143 183.70




































Fig. 1. Age-specific incidence rates (per 100,000) of prostate can-
cer in male population of Belgrade, 1999–2005.
Discussion
On the international level, prostate cancer is a signifi-
cant public health issue. Wide variation in its incidence
persists among countries. For example, the rates in the
USA are 2.5 times higher than those in the UK and al-
most 10 times than the levels in Japan9,10. The average
standardized incidence rate in Belgrade for the period
1999–2005 is 33.6/100.000 which is 3.7 times lower than
in the USA (standardized incidence rate for 2002 was
124.8/100,000)11. But in comparison with the countries
in the region (Croatia 24.5, Macedonia 27.5, Slovenia
30.9, Bosnia and Herzegovina 19.0 in 2002)11 the inci-
dence rate (per 100,000) in Belgrade is higher.
There has been long-term increase in the incidence of
prostate cancer in many countries in the world like
Australia12, Denmark13, Germany14, the Netherlands15,
Sweden16 and Canada17, and the explanation for this can
be found in the increased use of prostate specific antigen
(PSA) tests and transurethral resection18–23. In Belgrade,
the cancer incidence rates also increased during the ob-
served period and it is not clear whether this increase
was due to changes in prostate cancer risk factors, begin-
ning of use of PSA test in its early detection, or in both. A
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TABLE 2
STANDARDIZED INCIDENCE AND MORTALITY RATES (PER 100,000) OF PROSTATE CANCER IN MALE POPULATION OF BELGRADE
Years Number of cases Standardized incidence rates* Number of deaths Standardized mortality rates*
1990 – ** – 103 9.11
1991 – – 97 8.49
1992 – – 100 8.82
1993 – – 94 8.45
1994 – – 103 9.15
1995 – – 118 10.50
1996 – – 101 8.77
1997 – – 110 9.56
1998 – – 120 10.14
1999 344 29.34 153 13.36
2000 377 31.92 133 11.54
2001 378 32.08 159 13.85
2002 386 33.13 167 14.65
2003 414 35.28 213 18.58
2004 429 36.35 166 14.55
2005 435 36.86 161 14.16
2006 – – 204 17.93
Average 395 33.57 135 11.86
*According to the Segi’s world population6.
**No relevant morbidity data were available.
TABLE 3
AVERAGE AGE-SPECIFIC MORTALITY RATES (PER 100,000) AND MORTALITY TREND FOR PROSTATE CANCER IN MALE POPULATION
OF BELGRADE, 1990–2006
Age groups Mortality rates Equation of the regression analyses AAPC* 95% CI**
50 0.19 *** 0.1**** –14.3, 16.8
50–59 6.53 y=2.77+0.42x 1.4**** –11.4, 16.0
60–69 39.21 *** 0.8**** –0.8, 2.4
70–79 158.18 y=61.92+10.70x 7.2**** 5.3, 9.1
80+ 363.03 y=183.08+19.99x 5.3**** 2.8, 7,8
Total 17.78 y=9.86+0.88x 5.0**** 3.8, 6.1
*Average Annual Percentage Change
**Confidence Interval
***None of the regression analysis models is adequate for the presented data.
****The AAPC is statistically significant from zero.
further rise can be expected in the upcoming years as the
use of the sofisticated methods in the early detection of
diseases, such as PSA test, becomes more widespread
and frequent.
Our results are in accordance with the numerous epi-
demiological studies which have shown that prostate
cancer incidence rates are rare in the age group 50 years
and younger, rising very steeply with the increase of
age10,21,24. Like in the USA21, the rates in Belgrade were
lower among men aged 80 years and over than among the
age group 70–79. These patterns suggest that increases
in rates related to improved diagnosis and screening
were more pronounced among men aged 70–79 years
compared with the oldest men.
Prostate cancer standardized mortality rates (per
100,000) in Belgrade population almost doubled during
the period observed (from 9.1 in 1990 to 17.9 in 2006).
The average standardized mortality rate of prostate can-
cer in Belgrade of 11.9 per 100,000, is similar to the rates
in the region (Croatia 13.5, Macedonia 8.7, Slovenia 18.8,
Bosnia and Herzegovina 10.8 per 100,000 in 2002)11. In
some Asian countries, like Singapore and Japan prostate
cancer mortality rates have been increasing probably as
a consequence of the adoption of unhealthy lifestyle from
the West, so called »westernization«, including increased
intake of animal fat, obesity, insulin resistance, and
physical inactivity25. On the contrary, in many developed
countries like USA, Great Britain and Canada prostate
cancer mortality rates have been decreasing26. In Spain27,
the age-standardized mortality rates reached their peak
value in 1996 and then declined at an annual rate of
2.7%. The tendency of prostate cancer mortality reduc-
tion from year 1996 was also observed in Chile28. The
main reason for this may be found in the increased usage
of PSA screening and in better treatment of the early
stage disease. The average annual increase of age-spe-
cific mortality rates in Belgrade over the 17-year time pe-
riod was 5%.
As it was mentioned previously PSA screening was in-
troduced in a number of developed countries to detect
prostate cancer at an early stage and to reduce prostate
cancer mortality29,30. Recently Bouchardy et al.31 per-
formed joinpoint analysis to examine prostate cancer
mortality trends in 38 countries. Their results suggest
that PSA screening may be effective in reducing mortal-
ity from prostate cancer.
In Serbia there is still reluctance to use PSA as a sole
indication for biopsy32. To our knowledge national pros-
tate cancer screening programs do not exist in the South
Eastern European countries. Opportunistic prostate can-
cer screening uptake is low in the Croatian adult popu-
lation33, and there is no evidences about its use in other
countries in the region.
The increase of prostate cancer incidence and mortal-
ity, during the observed period in Belgrade population,
indicate urgent need for Serbian health professionals to
adopt existing cancer control and preventive measures,
such as maintaining a healthy body weight, getting regu-
lar physical activity, and consuming a diet low in animal
fat and high in fruits and vegetables1. A national policy
including PSA screening should be considered in the
light of the newest findings. The most recent studies34,35
have highlighted that a shared decision making approach
to PSA screening is highly appropriate, given the likeli-
hood of harm due to overdiagnosis. However, both the
PLCO (Prostate, Lung, Colorectal and Ovarian Cancer
Screening)34 and the ERSPC (European Randomized Stu-
dy of Screening for prostate Cancer)35 trials are ongoing
and further updates should be expected.
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RASTU^A INCIDENCIJA I SMRTNOST OD RAKA PROSTATE U POPULACIJI GRADA BEOGRADA
S A @ E T A K
Cilj ovoga rada bio je analizirati epidemiolo{ku situaciju raka prostate na populaciji grada Beograda. Podatci o obo-
ljevanju prikupljeni su na Institutu za javno zdravlje Srbije za period 1999–2005. Podaci o smrtnosti za razdoblje
1990–2006 dobivenu su iz Republi~kog zavoda za statistiku. Prosje~na standardizirana incidencija i stopa smrtnosti od
raka prostate su 33,57 i 11,86. Standardizirana incidencija raka prostate stalno se pove}ava od 29,34 na 100 000 u 1999.
godina na 36,86 na 100 000 u 2005. godini. U promatranom razdoblju, stopa smrtnosti znatno se pove}ava u dobnim
skupinama 50–59 (y=2,77+0,42x, p=0,015), 70–79 (y=61,92+10,70x, p=0,000) i 80+ (y=183,08+19,99x, p=0,000).
Prosje~na godi{nja stopa promjene bila je najve}a (7,2%) za dobnu skupinu 70–79, najmanja za najmla|u dobnu sku-
pinu (50), i 5% za sve dobne skupine. Pove}anost incidencije raka prostate i smrtnosti tijekom promatranog perioda u
beogradskoj populaciji indicira urgentnu potrebu za srpske zdravstvene djelatnike da usvoje postoje}e mjere kontrole
raka i preventivne mjere zasnovane na dokazima. Tako|er, nacionalna politika trebala bi razmotriti i screening speci-
fi~nog antigena (PSA) prostate.
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